TeamViewer: The Return of the Software Pioneer
TeamViewer has already weathered tough times, during which the Göppingen-based software company’s stock took a significant hit. But the tide seems to be gradually turning. A closer look at the latest financial results certainly offers cause for hope. The company increased its net income in the first quarter by a whopping 15% to around EUR 34 million. That amounts to EUR 0.22 per share. At the same time, the equity ratio improved from 10% to 13%. These are small steps in the right direction.
New major contracts for the TeamViewer ONE platform, including ones from airlines and financial service providers, underpin this trend. Even the strict US regulatory authorities have now signaled that the software is on track to receive the coveted FedRAMP status.
On the stock market, this already triggered the start of a strong rebound in the spring, beginning around mid-April. Although the share price recently slipped again from EUR 6.68 to EUR 4.58 following an overbought phase, the chart pattern remains intriguing. The stock has now turned upward again and is currently trading around EUR 5.58. It is thus forming a classic inverted head-and-shoulders pattern. The key now is to sustainably break through the resistance at the 200-day moving average around EUR 5.70. A strong second quarter could be the decisive catalyst here.
From 1-to-1 connectivity in the workplace, we now dive into the microscopically small but financially massive world of modern medicine and the biotech sector.
BioNTech: The Path to Oncology Dominance
The Mainz-based company BioNTech is undergoing a massive corporate transformation. The former COVID-19 vaccine giant is radically restructuring itself. The goal is clearly defined: BioNTech aims to become one of the world’s leading oncology companies by the end of the decade. Its coffers are brimming with EUR 17.2 billion. This financial cushion is urgently needed, as the development of cancer drugs devours vast sums of money.
Management is currently preparing for the market launch of T-Pam. This drug, designed to treat a specific type of cervical cancer, is not yet intended to dethrone the major competitors. Rather, it serves as a test run. BioNTech aims to gain valuable experience in sales and market access through this initiative. The company’s real hope rests on the antibody Pumitamig. Several Phase 3 trials are currently underway worldwide. At the same time, another drug candidate for lung cancer is being tested.
However, this radical corporate restructuring is also taking its toll. Approximately 1,860 jobs are being cut, causing considerable unrest among the workforce. The stock market is currently viewing this transformation process with a certain degree of skepticism. The stock has recently been hovering around EUR 78.50 and is struggling with the 50-day moving average at EUR 79.21. The share price is still a good distance away from this year’s high of EUR 105.80, reached in January. Analysts, however, see greater potential and are setting price targets above EUR 105. Upcoming study data will show whether this bet on the future pays off.
Whether it is software or modern cancer research—all these innovations require a physical foundation: raw materials. And that brings us to Antimony Resources.
Antimony Resources: Raw Material Wealth Deep in the Earth
Antimony is perhaps one of the most important minerals that many investors have never heard of. It is crucial for the defense industry, modern semiconductors, and energy storage. In light of geopolitical tensions and export restrictions imposed by China, Western nations are desperately seeking their own sources. This is exactly where Antimony Resources comes into play. The Canadian exploration company is fully focused on this critical element. The company’s website reads like a wake-up call to industry, as the goal is to break the dependence on Asian supply chains.
The management team, led by geologist James Atkinson, is focusing on the Bald Hill project in the province of New Brunswick. The latest news from the drilling program looks quite promising. In early July, the company reported fantastic assay results from the main zone. The drill holes returned high-grade values exceeding 33% antimony. These zones extend to depths of 100-150 m.
Just a few days earlier, at the end of June, there was even a surprise: by using artificial intelligence in data analysis, the team discovered significant gold deposits. The rock samples contained an average of 1.14 g/t of gold, with a peak of 1.88 g/t. This adds an entirely new economic dimension to the entire project, in addition to the main raw material, antimony.
The extent of the deposits is also encouraging. Rock samples from the so-called central zone also yielded excellent antimony and gold values just a few days earlier. This zone appears to be directly adjacent to the main zone, and would extend the area of potential mineralization to over 1 km.
Despite this underground progress and the associated good news, Antimony Resources’ stock has been trending downward in the market for several weeks. The share price is currently trading at around CAD 0.53. A look at the chart, however, shows clear horizontal support at this level. Here, or slightly lower, a solid bottom could now form. If the turnaround succeeds from this base, the next technical targets are CAD 0.70 and then CAD 0.80.
We see three investment opportunities—or all three combined.
TeamViewer must now prove that the turnaround is sustainable and that its software business is growing reliably again.
Although BioNTech is currently burning through cash, it has the absolute potential to revolutionize cancer therapy worldwide.
Antimony Resources consistently delivers strong drilling results and operates in a strategically vital commodities market. The company benefits directly from the global demand for critical minerals. The latest discoveries of antimony and gold underscore the quality of the project in Canada. If the stock finds a bottom at its current level, this presents an exciting turnaround opportunity for risk-aware investors.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.